Top in endocrinology: Novel sensor for diabetes; metabolic effects of testosterone therapy
Click Here to Manage Email Alerts
A noninvasive sensor may measure glucose values by using dielectric spectroscopy to scan radiofrequencies, according to a speaker at the American Association of Clinical Endocrinology Annual Meeting.
Dominic Klyve, PhD, a professor of mathematics at Central Washington University and Know Labs Data Science & Engineering, said the sensor holds promise and could help reduce waste, lower health costs and make glucose measurements pain and needle free. It was the top story in endocrinology last week.
Another top story was about a study that found similar changes in most cardiometabolic measures among men receiving lifestyle intervention plus testosterone therapy vs. placebo.
Read these and more top stories in endocrinology below:
Noninvasive radiofrequency sensor with machine learning may accurately measure glucose
A noninvasive device using a radiofrequency sensor may be able to measure glucose levels for people with diabetes in the future, according to a speaker at the AACE Annual Meeting. Read more.
Testosterone therapy not tied to additional metabolic benefits for older men with obesity
Testosterone therapy did not improve cardiometabolic measures for older men with obesity and hypogonadism receiving lifestyle intervention, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.
Q&A: Providers need to shift course with diabetes medications, technology during pregnancy
The rise in use of diabetes medications and continuous glucose monitoring had led to new challenges for treating pregnant women with diabetes. Read more.
Most providers start osteoporosis therapy without full assessment of secondary causes
Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting. Read more.
New guidance, technology on the horizon for thyroid nodule risk assessment
New risk stratification guidance for classifying thyroid nodules may come soon as imaging technology continues to evolve, according to a speaker at the AACE annual meeting. Read more.